Vimarsana
Biggest News Aggregation in the World

Page 25 - Docket Number News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Docket Number. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Docket Number Today - Breaking & Trending Today

Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatme - Vimarsana News

Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatme

Clinical / Medical

Source: fda.gov
Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer (DTC) Promotional Labeling and Advertisements - Vimarsana News

Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer (DTC) Promotional Labeling and Advertisements

Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer (DTC) Promotional Labeling and Advertisements

Source: fda.gov
U.S. House Natural Resources Committee Hearing Requiring Withdrawal of Controversial Proposed Rule | Snell & Wilmer - Vimarsana News

U.S. House Natural Resources Committee Hearing Requiring Withdrawal of Controversial Proposed Rule | Snell & Wilmer

The U. S. House Committee on Natural Resources hearing held on Thursday, June 15, 2023, was singularly focused on H.R. 3397, sponsored by Rep. John R. Curtis (R-UT-3), which requires...

Alternative Procedures for the Manufacture of Cold-Stored Platelets - Vimarsana News

Alternative Procedures for the Manufacture of Cold-Stored Platelets

This notice is being issued under 21 CFR 640.120(b) to respond to a public health need and address the urgent and immediate need for platelets for the treatment of active bleeding when conventional platelets are not available, or their use is not practical.

Source: fda.gov
CVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Containing Active Pharmaceutical Ingredients Considered to Be Soluble in Aqueous Media - Vimarsana News

CVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Containing Active Pharmaceutical Ingredients Considered to Be Soluble in Aqueous Media

This document describes how CVM intends to evaluate requests for waiving the requirement for performing in vivo bioequivalence studies for animal drugs administered orally as soluble powders or as Type A medicated articles manufactured from water soluble APIs.

Source: fda.gov